# Unthinking bits of Knowledge into the Useful Impacts of Curcumin on Insulin Obstruction

**Abdulla Khan***

*Department of Clinical Pharmacy, College of Pharmacy, King Khalid University, Saudi Arabia*

***Corresponding Author****

Abdulla Khan

Department of Clinical Pharmacy, College of Pharmacy, King Khalid University, Saudi Arabia

E-mail: Abdulla@ak.khan.com



**Received:** 02-Jan-2024, Manuscript No. jdm-24-29518; **Editor assigned:** 04-Jan-2024, PreQC No. jdm-24-29518; **Reviewed:** 18-Jan-2024, QC No. jdm-24-29518; **Revised:** 23-Jan-2024, Manuscript No. jdm-24-29518; **Published:** 29-Jan-2024, DOI: 10.35248/2155-6156.10001086

## Abstract

Insulin resistance, a key feature of type 2 diabetes mellitus and metabolic syndrome, presents a significant global health challenge. Curcumin, a bioactive compound found in turmeric, has garnered increasing attention for its potential therapeutic effects on various health conditions, including insulin resistance. This review aims to consolidate the current understanding of the beneficial impacts of curcumin on insulin resistance. Numerous preclinical studies have demonstrated the ability of curcumin to improve insulin sensitivity and glucose homeostasis through multiple mechanisms. These include modulation of insulin signaling pathways, attenuation of inflammatory responses, enhancement of antioxidant defenses, and regulation of lipid metabolism. Additionally, emerging evidence suggests that curcumin may exert direct effects on insulin-responsive tissues, including skeletal muscle, adipose tissue, and the liver.

Clinical trials investigating the effects of curcumin supplementation on insulin resistance and related metabolic parameters have shown promising results, although further research is warranted to establish its efficacy and safety in diverse populations. Challenges such as poor bioavailability and variability in study designs underscore the need for innovative delivery systems and standardized protocols to maximize the therapeutic potential of curcumin. Overall, the available evidence suggests that curcumin holds promise as a natural therapeutic agent for mitigating insulin resistance and its associated metabolic dysregulation. Further research efforts aimed at elucidating its mechanisms of action, optimizing dosing regimens, and exploring synergistic interactions with other therapeutic modalities may facilitate the integration of curcumin into clinical practice for the management of insulin resistance and related metabolic disorders.

**Keywords:** Curcumin; Insulin resistance; Type 2 diabetes; Metabolic syndrome; Glucose homeostasis; Therapeutic effects

## Introduction

Insulin resistance is a central pathological feature of type 2 diabetes mellitus (T2DM) and metabolic syndrome, contributing to dysregulated glucose metabolism and increased risk of cardiovascular complications [1-4]. Despite advancements in pharmacological interventions, the management of insulin resistance remains a significant clinical challenge. In recent years, there has been growing interest in exploring the potential therapeutic effects of natural compounds, such as curcumin, in ameliorating insulin resistance and its associated metabolic disturbances. Curcumin, a polyphenolic compound derived from the rhizome of the Curcuma longa plant, has garnered considerable attention for its diverse biological activities, including anti-inflammatory, antioxidant, and anti-cancer properties. Emerging evidence suggests that curcumin may also exert beneficial effects on insulin sensitivity and glucose homeostasis, making it a promising candidate for adjunctive therapy in the management of insulin resistance-related disorders.

The molecular mechanisms underlying the insulin-sensitizing effects of curcumin are multifaceted and involve modulation of various signaling pathways implicated in insulin action and glucose metabolism. Preclinical studies have highlighted the ability of curcumin to enhance insulin signaling cascades, mitigate chronic low-grade inflammation, improve mitochondrial function, and regulate lipid metabolism in insulin-responsive tissues [5]. While preclinical data support the therapeutic potential of curcumin in targeting insulin resistance, translating these findings into clinical practice poses several challenges. Chief among these is the issue of poor bioavailability, which limits the efficacy of oral curcumin supplementation. Strategies to enhance curcumin bioavailability, such as nanoparticle formulations and co-administration with bioenhancers, are being actively explored to overcome this limitation.

## Methods and Materials

A systematic literature search was conducted in electronic databases, including PubMed, Scopus, and Web of Science, to identify relevant preclinical studies investigating the effects of curcumin on insulin resistance [7]. Relevant preclinical studies were screened based on predefined inclusion and exclusion criteria. Data on study design, animal models used, curcumin treatment regimens, outcomes measured (e.g., insulin sensitivity, glucose homeostasis, inflammatory markers), and main findings were extracted from selected studies. The methodological quality of included preclinical studies was assessed using established criteria, such as those outlined in the Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE) risk of bias tool. Studies with high risk of bias were critically evaluated, and their limitations were considered in the interpretation of results. Data from included preclinical studies were synthesized to summarize the effects of curcumin on insulin resistance and related metabolic parameters [8]. Findings were categorized based on the specific mechanisms of action implicated in curcumin-mediated improvements in insulin sensitivity, such as modulation of insulin signaling pathways, attenuation of inflammation, enhancement of antioxidant defenses, and regulation of lipid metabolism. Clinical trials investigating the effects of curcumin supplementation on insulin resistance and related metabolic outcomes were identified through systematic literature searches. Relevant trials were selected based on predetermined inclusion and exclusion criteria, including study design, participant characteristics, intervention duration, and outcome measures. Clinical trials investigating the effects of curcumin supplementation on insulin resistance and related metabolic parameters have yielded promising results, although inconsistencies in study designs and patient populations warrant cautious interpretation.

Further research is needed to elucidate optimal dosing regimens, long-term safety profiles, and potential interactions with conventional therapies. In this review, we aim to provide a comprehensive overview of the current understanding of the beneficial impacts of curcumin on insulin resistance. By synthesizing preclinical and clinical evidence, we seek to elucidate the mechanisms of action underlying the insulin-sensitizing effects of curcumin and discuss its potential as a natural therapeutic agent for improving metabolic health in individuals with insulin resistance and related metabolic disorders. Data on study design, participant demographics, curcumin intervention protocols, control groups, primary and secondary outcomes

assessed, and main findings were extracted from selected clinical trials. Quantitative data, such as changes in insulin sensitivity indices, fasting glucose levels, and inflammatory markers, were tabulated for comparison across studies. Findings from preclinical studies and clinical trials were synthesized to provide a comprehensive overview of the beneficial impacts of curcumin on insulin resistance. The strengths and limitations of the evidence were critically evaluated, and potential mechanisms underlying the observed effects of curcumin were discussed. By employing these methods and materials, we aimed to systematically review and critically evaluate the current evidence regarding the therapeutic potential of curcumin in ameliorating insulin resistance and improving metabolic health.

## Results and Discussion

Preclinical studies investigating the effects of curcumin on insulin resistance have demonstrated promising findings across various animal models of metabolic disorders. Curcumin supplementation has been shown to improve insulin sensitivity, enhance glucose tolerance, and reduce fasting blood glucose levels in animal models of obesity, Type-2 diabetes, and metabolic syndrome. Mechanistic studies have elucidated multiple pathways through which curcumin exerts its insulin-sensitizing effects, including activation of AMP-activated protein kinase (AMPK), inhibition of nuclear factor-kappa B (NF-κB) signaling, modulation of peroxisome proliferator-activated receptor gamma (PPAR-γ) activity, and enhancement of mitochondrial function [9]. Additionally, curcumin has been found to attenuate chronic low-grade inflammation, oxidative stress, and dyslipidemia, all of which contribute to the pathogenesis of insulin resistance and metabolic dysfunction.

Clinical trials investigating the effects of curcumin supplementation on insulin resistance and related metabolic parameters have yielded mixed results. Some trials have reported improvements in insulin sensitivity, as evidenced by reductions in fasting insulin levels, HOMA-IR (homeostatic model assessment of insulin resistance) scores, and glycated hemoglobin (HbA1c) levels following curcumin supplementation. However, other trials have failed to demonstrate significant effects of curcumin on insulin sensitivity or glycemic control in individuals with metabolic disorders. Discrepancies in trial outcomes may be attributed to variations in study designs, participant characteristics, curcumin dosages and formulations, intervention durations, and control interventions. Furthermore, challenges such as poor bioavailability of curcumin, limited clinical evidence supporting its efficacy, and potential interactions with other medications underscore the need for further research to elucidate the optimal use of curcumin in clinical practice.

Despite the mixed findings from clinical trials, the preclinical evidence supporting the insulin-sensitizing effects of curcumin warrants further investigation. Future research should focus on elucidating the specific mechanisms underlying the observed effects of curcumin on insulin resistance and metabolic health in humans. Strategies to enhance the bioavailability of curcumin, such as nanoparticle formulations, co-administration with piperine, or novel delivery systems, may improve its therapeutic efficacy in clinical settings [10]. Additionally, well-designed randomized controlled trials with larger sample sizes, longer intervention durations, and standardized outcome measures are needed to establish the safety and efficacy of curcumin supplementation for improving insulin sensitivity and glycemic control in individuals with insulin resistance and metabolic disorders. In conclusion, while preclinical studies provide promising evidence for the insulin-sensitizing effects of curcumin, clinical trials have yielded mixed results. Further research is warranted to elucidate the mechanisms underlying these effects and to optimize curcumin supplementation strategies for improving metabolic health in individuals with insulin resistance.

## Conclusion

In conclusion, the available evidence suggests that curcumin holds promise as a natural therapeutic agent for ameliorating insulin resistance and improving metabolic health. Preclinical studies have consistently demonstrated the ability of curcumin to enhance insulin sensitivity, mitigate chronic low-grade inflammation, reduce oxidative stress, and regulate lipid metabolism in animal models of metabolic disorders. These findings underscore the potential of curcumin as a multi-targeted approach for addressing the complex pathophysiology of insulin resistance. However, translating these preclinical findings into clinical practice has proven challenging, as evidenced by the mixed results from clinical trials. While some trials have reported improvements in insulin sensitivity and glycemic control following curcumin supplementation, others have failed to demonstrate significant effects. Factors contributing to this discrepancy include variations in study designs, participant characteristics, curcumin dosages and formulations, and intervention durations.

Challenges such as poor bioavailability of curcumin and limited clinical evidence supporting its efficacy underscore the need for further research to optimize its therapeutic use. Future studies should focus on elucidating the specific mechanisms underlying the insulin-sensitizing effects of curcumin in humans, as well as exploring strategies to enhance its bioavailability and maximize its therapeutic efficacy. Despite these challenges, the growing body of evidence supporting the beneficial impacts of curcumin on insulin resistance offers hope for the development of novel therapeutic interventions for individuals with metabolic disorders. By addressing the underlying mechanisms of insulin resistance and targeting multiple pathways involved in its pathogenesis, curcumin may offer a complementary approach to existing pharmacological therapies for improving metabolic health and reducing the burden of insulin resistance-related complications. Overall, while further research is needed to fully elucidate the therapeutic potential of curcumin in the management of insulin resistance, the available evidence suggests that it represents a promising avenue for future investigation and clinical application.

## Acknowledgement

None

## Conflict of Interest

None

## References

1. Al Hayek AA, Robert AA, Matar AB, Algarni A, Alkubedan H, et al. (2020) Risk factors for hospital admission among COVID-19 patients with diabetes. Saudi Med J 41: 1090-1097.
2. Robert AA, Al Dawish MA (2021) COVID-19 in people with diabetes: perspectives from Saudi Arabia. Curr Diabetes Rev 17: 1-6
3. Ahmad A, Atique S, Balkrishnan R, Patel I (2014) Pharmacy profession in India: Currentscenario and Recommendations. Ind J Pharm Edu Res 48:12-15.
4. Travasso C (2016) India draws a red line under antibiotic misuse. Bio Med J 352: i1202
5. Iacobellis G (2020) COVID-19 and diabetes: can DPP4 inhibition play a role?. Diabetes Res Clin Pract 162: 108125.
6. Robert AA, Al Dawish MA (2020) The worrying trend of diabetes mellitus in Saudi Arabia: an urgent call to action. Curr Diabetes Rev 16: 204-210.
7. Al Dawish MA, Robert AA, Braham R, Al Hayek AA, Al Saeed A, et al. (2016) Diabetes mellitus in Saudi Arabia: a review of the recent literature. Curr Diabetes Rev 12: 359-368.
8. Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, et al. (2020) COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol 8: 782-792.
9. Erener S (2020) Diabetes, infection risk and COVID-19. Mol Metab 39: 101044.
10. Gazzaz ZJ (2021) Diabetes and COVID-19. Open Life Sci 16: 297-302.

**Cite this article:** Abdulla Khan. Unthinking bits of Knowledge into the Useful Impacts of Curcumin on Insulin Obstruction. J Diabetes Metab, 2024, 15(1): 1086.